ArticleIntestinal Failure (New York, N.Y.)
Exploring the role of pancreatic enzyme replacement therapy in patients with short bowel syndrome: Nutritional and Anthropometric Outcomes.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic enzyme replacement therapy (PERT) has been proposed as a treatment for patients with short bowel syndrome (SBS) to address fat malabsorption and promote growth. However, research on the effectiveness of PERT in this population remains limited. This study aims to investigate the impact of PERT on nutritional status and anthropometric measurements in individuals with SBS. Material and Methods: We retrospectively analyzed medical records of 14 patients with SBS under 25 years at our institution who were prescribed PERT over a twelve-year period. Nutritional status factors including enteral and parenteral calorie intake, fat-soluble vitamin deficiency, vitamin supplement use, along with anthropometric measurements, were assessed across three-time frames: 6 months pre-PERT administration, at PERT initiation, and 6 months post-PERT. Statistical tests, including Mann-Whitney rank sum, Chi-squared, and regression tests, were conducted with a significance level set at 0.05. Results: Of the 14 patients with SBS who were using PERT, six had elastase levels suggesting pancreatic insufficiency (PI). Among the 14 patients, one discontinued parenteral nutrition (PN) support after 6 months of PERT. Fat soluble vitamin deficiency persisted among three patients despite vitamin supplementation. Six months post-PERT, there was a non-significant decrease in all mean anthropometric z-scores, except for the weight z-scores (p > 0.84). Significant decreases in mean BMI z-scores (p = 0.03) and non-significant reductions in all remaining anthropometric measurements (p > 0.13) were observed among patients with PI following 6 months of PERT use. Conclusion: PERT utilization may not significantly address fat malabsorption or promote growth in patients with SBS, likely due to anatomical constraints of a shortened bowel that affect nutrient absorption. Further investigation is warranted to determine the efficacy of PERT as a treatment tool for patients with SBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.